In a multicenter study aimed at assessing the diagnostic utility of CSF YKL-40 in differentiating clinical Alzheimer’s disease from other neurodegenerative diseases, the biomarker discriminated Alzheimer’s disease from frontotemporal dementia [195]. This evidence concerns the gene CHI3L1 and Alzheimer disease.